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Amyloid-b precursor protein (APP) was identified on expression cloning from a human
placenta cDNA library as a gene product that modulates the activity of membrane-type
matrix metalloproteinase-1 (MT1-MMP). Co-expression of MT1-MMP with APP in
HEK293T cells induced cleavage and shedding of the APP ectodomain when
co-expressed with APP adaptor protein Fe65. Among the MT-MMPs tested, MT3-MMP
and MT5-MMP also caused efficient APP shedding. The recombinant APP protein was
cleaved byMT3-MMP in vitro at the A463-M464, N579-M580, H622-S623, and H685-Q686 peptide
bonds, which included a cleavage site within the amyloid b peptide region known to
produce a C-terminal fragment. The Swedish-type mutant of APP, which produces a
high level of amyloid b peptide, was more effectively cleaved by MT3-MMP than
wild-type APP in both the presence and absence of Fe65; however, amyloid b peptide
productionwasnotaffectedbyMT3-MMPexpression.ExpressionofMT3-MMPenhanced
Fe65-dependent transactivationbyAPP fused to theGal4DNA–bindingand transactiva-
tion domains. These results suggest that MT1-MMP, MT3-MMP and MT5-MMP should
playan important role in the regulationofAPP functions in tissues including the central
nervous system.
Key words: amyloid-b precursor protein, cleavage, MMP, MT-MMP.
Abbreviations: Ab, amyloid b peptide; APP, amyloid-b precursor protein; BB94, [4-(N-hydroxyamino)-2R-iso-
butyl-3-S-(thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide; CTF, carboxyl-terminal fragment;
DAPT, N-[N-(3,5-difluorophenacetyl-L-alanyl)-S-phenylglycine-t-butyl ester]; GST, glutathione S-transferase;
MMP, matrix metalloproteinase; MT-MMP, membrane-type matrix metalloproteinase; PAGE, polyacrylamide
gel electrophoresis; PVDF, polyvinylidene difluoride.
Amyloid-b precursor protein (APP) is a type I trans-
membrane glycoprotein constitutively expressed in many
types of mammalian cells. As its name implies, APP was
initially identified as the precursor of amyloid b peptide
(Ab), the principal component of amyloid plaques in the
pathogenesis of Alzheimer’s disease (1). Under physiologi-
cal conditions, APP is processed through a series of
proteolytic cleavages by enzymes referred to as secretases
(2, 3). This results in shedding of the large N-terminal
domain, the generation of 40 or 42-residue long Ab pep-
tides, and the release of the C-terminal fragment (CTF).
Recently, accumulating evidence has emphasized the
potential importance of APP CTFs, including their involve-
ment in gene transactivation. In this case, the sequential
proteolytic processing of APP is strikingly similar to that of
other proteins that undergo regulated intramembrane pro-
teolysis, whereby upon release, the cytoplasmic tail enters
the nucleus with Fe65 as its transcriptional coactivator
and regulates gene transactivation (4–6).
Matrix metalloproteinases (MMPs) comprise a family
of Zn2+-dependent enzymes that are known to cleave
extracellular matrix proteins under normal and pathologi-
cal conditions (7–9). Presently, at least 28 mammalian
MMPs have been identified by cDNA cloning, and they
can be subgrouped into soluble type MMPs and membrane
type MMPs (MT-MMPs) (9, 10). MMPs are overexpressed
in various human malignancies and have been thought to
contribute to tumor invasion and metastasis by degrading
extracellular matrix components (7, 11). Thus, the level of
MMP expression correlates with the invasiveness or malig-
nancy of tumors (12, 13). In particular, MT1-MMP,
MMP-2, MMP-7 and MMP-9 have been reported to be
most closely associated with tumor invasion and metasta-
sis. Although degradation of the extracellular matrix is an
important aspect of MMP biology, growing evidence has
demonstrated the involvement of MMPs in specific proces-
sing resulting in activation or degradation of cell surface
receptors and ligands. Fas ligand (14), tumor necrosis
factor-a (15), the ectodomain of fibroblast growth factor
receptor-1 (16), the heparin binding epidermal growth fac-
tor (17), and interleukin-8 (18) have been reported to be
released or activated by MMPs. MMPs also cleave and
inactivate interleukin-1b (19), insulin-like growth factor–
binding proteins (20), fibrinogen and factor XII (21), the CC
chemokine MCP-3 (22), the CXC chemokines stromal cell–
derived factor-1a and b (23, 24), metastasis suppressor
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gene product KiSS-1/metastin (25), heparin sulfate proteo-
glycan syndecan-1 (26), small leucine-rich proteogycan
lumican (27), and apolipoprotein E (28).
We previously developed an expression cloning method
for the screening of genes that modulate pro-MMP-2
activation mediated by MT1-MMP, and also for gene pro-
ducts that serve as substrates for MT1-MMP (25–30). In
this study, we demonstrated that in addition to the most
abundant MT-MMP (MT1-MMP), MT3-MMP and
MT5-MMP, whose expression is the highest in the brain,
caused cleavage and shedding of the APP ectodomain to
generate CTFs that may contribute to Fe65-dependent
transactivation.
MATERIALS AND METHODS
Materials—Dulbecco’s modified Eagle’s medium
(DMEM) was obtained from Sigma (St Louis, MO). Primers
were synthesized by Genset (Kyoto, Japan). A human pla-
centa cDNA library constructed in the pEAK8 expression
vector was obtained from EdgeBio Systems (Gaithersburg,
MD). The recombinant MT3-MMP catalytic domain tagged
with the FLAG epitope at the C-terminus was prepared as
described previously (31, 32). Monoclonal antibodies
against the FLAG and HA epitopes were purchased from
Sigma. The anti–MT1-MMP (113-5B7), MT2-MMP (162-
4E3), and MT3-MMP (117-4E1) monoclonal antibodies
were from Daiichi Fine Chemical Co., Ltd. (Takaoka,
Japan). The APP monoclonal antibodies 6E10 and 4G8,
specific for Ab peptide residues 1–17 (APP amino acid resi-
dues 672–688) and 17–24 (688–695), respectively, were
from Signet (Dedham, MA). The synthetic Ab40 peptide
was synthesized by Genset.
Cell Culture—Human embryonic kidney HEK293T and
COS-1 cells were obtained from ATCC and cultured in
DMEM supplemented with 5% fetal calf serum.
Construction of Expression Plasmids—Expression plas-
mids for MMP-2, MMP-9, MT1-MMP, MT3-MMP and MT-
MMPs with the FLAG epitope following the furin cleavage
sequence were prepared as described previously (33–36).
An expression plasmid for APP tagged with the FLAG epi-
tope at the C-terminus (APP-F) was constructed by PCR
using an APP reverse primer with an extra BglII site
(underlined) starting at nucleotide 2483 of the APP gene
(GeneBank accession number NM_000484) (GG-
AGATCTGTTCTGCATCTGCTCAAAGAAC), as described
previously (29). An expression plasmid for APP tagged
with the FLAG epitope 4 amino-acid residues downstream
from the signal sequence (F-APP) was constructed by
inserting a double stranded DNA oligonucleotide encoding
the FLAG epitope (50: TC GAC TAC AAG GAC GAC GAT
GAC AAG GTA C; 30: CTT GTC ATC GTC GTC CTT GTA
GTC GA GTAC) at the KpnI site (nucleotide 251 of the APP
gene) of the APP cDNA fragment in the pEAK8 vector. A
cDNA fragment encoding the Swedish-type mutant APP,
in which Lys670-Met671 were substituted by Asn-Leu, was
generated by PCR amplification of F-APP cDNA using a
mutagenesis primer starting at nucleotide 2185 (AGGA-
GATCTCTGAAGTGAACTTGGATGCAG), which contains
mutated nucleotides (underlined). The pCMV.SPORT6-
Fe65 plasmid was purchased from Invitrogen (Carlsbad,
CA). An expression plasmid for Fe65 tagged with the HA
epitope at the C-terminus (Fe65-HA) was constructed by
inserting an Fe65 cDNA fragment into the pEAK-HA plas-
mid, which was amplified by PCR using an Fe65 reverse
primer with an extra XbaI site (underlined) starting at
nucleotide 2198 of the Fe65 gene (GeneBankTM accession
number BC010854) (AGTCTAGATGGGGTATGGGCCCC-
CAGCCGT) (29).
A bacterial expression plasmid for APP-GST was con-
structed as follows. An APP cDNA fragment encoding
amino acids 379 to 700 was generated by introducing a
BglII site at nucleotide 2294 by PCR using a mutation-
containing primer with an extra BglII sequence (under-
lined) (ATAGATCTTCTTTGCAGAAGATGTGGGTTC).
The fragment was cut with XhoI and BglII, and then
inserted into the XhoI/BglII site of the GST-CTC plasmid
as described previously (25).
An expression plasmid for APP-Gal4 fusion protein was
constructed as follows. A cDNA fragment encoding the
Gal4-DNA binding domain was PCR amplified using a for-
ward primer with an extra BglII site (underlined) starting
at nucleotide 13717 of the Gal4 gene (GeneBankTM acces-
sion number Z67751) (AGAGATCT AAGCTACTGTCTTC-
TATCGAAC) and a reverse primer with an extra BamHI
site (AGGGATCCCGATACAGTCAACTGTCTTTGA). The
amplified fragment was digested with BamHI and BglII,
and then inserted at the BglII site, which was created at
the 30 end of the APP cDNA fragment in the pSG-APP-
FLAG plasmid.
Expression Cloning—Expression cloning to identify
candidate genes whose products interact with MMP-2,
MMP-9 or MT1-MMP was carried out as described
previously (29).
Western Blotting—Transfection into HEK293T or COS-1
cells was performed with TransIT LT1 transfection reagent
(Mirus, Madison, WI). Cell lysates and proteins precipi-
tated from conditioned medium with 10% trichloroacetic
acid were analyzed by Western blotting using the indicated
antibodies. A goat anti–mouse IgG antibody conjugated
with Alexa Fluor 680 (Molecular Probes Inc., Eugene,
OR) was used as a second antibody. The signal was mon-
itored using a LI-COR Odyssey IR imaging system
(Lincoln, NE). For the detection of APP CTFs, cell lysates
and immunoprecipitated samples were separated by 4%/
10%/16% Tris-Tricine SDS-PAGE, and then transferred to
polyvinylidene difluoride (PVDF) membranes (Milipore,
Bedford, MA) at 1.5 mA/cm2 per gel, under semidry con-
ditions, using a Bio Craft model BE-320 electroblotter
(Tokyo, Japan). The blots were analyzed as described
above. For detection of the Ab peptide, culture super-
natants concentrated with trichloroacetic acid were sepa-
rated on 15% Bicine/Tris SDS-PAGE gels containing 8 M
urea, and then transferred to PVDF membranes. The Ab
peptide was detected with an anti–APP 6E10 antibody as
the primary antibody.
Cell Surface Biotinylation—HEK293T cells stably
expressing MT1-MMP or MT3-MMP were transfected
with expression plasmids for FLAG-APP and Fe65.
Forty-eight hours after transfection, the cells were washed
with cold PBS, and then incubated with PBS containing
0.5 mg/ml Biotin Sulfo-OSu (Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan) for 30 min at 4C. Unreacted
excess biotin was eliminated by washing with 25 mM
lysine in PBS. The cells were then lysed and then
subjected to immunoprecipitation with anti–FLAG M2
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antibody–conjugated agarose beads as described previously
(30). The immunoprecipitated material was separated
by 10% SDS-PAGE, and then blotted with IRDye800-
conjugated streptavidin (Rockland, Gilbertsville, PA) and
Alexa Fluor 680–conjugated FLAG M2 antibodies.
IRDye800 and Alexa Fluor 680 were detected with a
LI-COR Odyssey scanner as described above.
Determination of the Cleavage Sites of the APP Protein—
The recombinant APP-GST fusion protein was purified as
described previously (28). The APP-GST protein (5 mg) was
incubated with the recombinant MT3-MMP catalytic
domain (0.5 mg) in 30 ml of TNC buffer containing 0.03%
Brij at 37C for 3 h. The generated fragments were sepa-
rated by 12% SDS-PAGE and then blotted onto a PVDF
membrane. The N-terminal amino acid sequence of each
fragment was determined with a Beckman Coulter LF300
amino acid sequencer.
Luciferase Transactivation Assay—COS-1 cells were
plated on 12-well plates 24 h before transfection. For
the luciferase transactivation assay, the pFR-Luc
trans-reporter plasmid (Stratagene, La Jolla, CA), renilla
luciferase control plasmid (pRL-SV40) (Promega, Madison,
WI), and pSG-APP-Gal4 were transfected with a control
plasmid or the MT3-MMP plasmid in the presence or
absence of APP transcriptional cofactor/coactivator Fe65.
The cells were harvested 2 days post-transfection, and
then analyzed with a Dual Luciferase Assay kit (Promega)
and a Lumat LB 9507 luminometer (EG&G Berthold,
Germany) following the manufacturer’s protocol. Assays
were performed at least three times and the luciferase
activity levels were normalized as to that of renilla
luciferase.
RESULTS
Screening of a Human Placenta cDNA Library—Aliquots
of plasmid DNA from a human placenta cDNA library
were cotransfected with MMP-2, MMP-9 and MT1-MMP
cDNA into HEK293T cells, and cell lysates were
analyzed by gelatin zymography (Fig. 1). A latent form
of pro-MMP-9, a latent form of pro-MMP-2, and an acti-
vated intermediate form of MMP-2 were detected as 92-,
68-, and 64-kDa bands, respectively (Fig. 1A). Processing of
pro-MMP-2 to generate the 62-kDa active form was found
to be more significant in lane 19 as compared with the other
lanes. From this positive pool of plasmid DNA, single
clones were prepared and each clone was transfected
into cells for second screening (Fig. 1B). Among 21 cDNA
clones, two were found to stimulate the processing of pro-
MMP-2 to its active form (lanes 3 and 17). The size of both
cDNA fragments was 3.5 kb, and their nucleotide
sequences were determined. Homology search analysis
revealed that both cDNAs encoded the integral type I
transmembrane glycoprotein APP (GenBank accession
no. NM_000484).
APP Promotes Pro-MMP-2 Processing by MT1-MMP—
The processing of pro-MMP-2 to an activated intermediate
form was enhanced by the expression of MT1-MMP in
HEK293T cells. Expression of APP alone did not have
any effect on pro-MMP-2 processing, but the fully active
form of MMP-2 was observed when APP was cotransfected
with MT1-MMP (Fig. 2A). This finding on gelatin zymo-
graphy clearly demonstrated that APP stimulated the acti-
vation of MMP-2 mediated by MT1-MMP. Therefore, we
next examined the effect of APP on MT1-MMP expression
to determine the basis for this stimulation. Immunoblot-
ting analysis confirmed that expression of APP enhanced
generation of the MT1-MMP active form, as detected using
both anti–Flag M2 and M1 antibodies (Fig. 2B).
Cleavage and Shedding of APP by MT-MMPs—We
previously showed that the type I transmembrane protein
syndecan-1 not only stimulates MT1-MMP–mediated pro-
MMP-2 processing, but also serves as a substrate for MT1-
MMP (26). This led us to examine whether APP could be a
substrate for MT1-MMP. To monitor the cleavage and
shedding of the APP ectodomain, an expression plasmid
Fig. 1. Expression cloning. (A) Ali-
quots of plasmid DNA from a human
placenta cDNA library were co-
transfected with MMP-9, MMP-2
and MT1-MMP into HEK293T cells
cultured in 96-well microplates as
described under ‘‘EXPERIMENTAL PRO-
CEDURES,’’ and cell lysates were sub-
jected to gelatin zymography at 48 h
post-transfection. Note that proces-
sing of pro-MMP-2 to the active form
(62 kDa) was enhanced in lane 19, as
indicated by the arrow. (B) Single
clones of plasmid DNA indicated to
be positive on the first screening
were analyzed as described above.
Note that pro-MMP-2 processing
was enhanced in lanes 3 and 17, as
indicated by the arrows.
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for F-APP was transfected into HEK293T cells, and the
shed APP fragments were detected with anti–FLAG M2
antibody (Fig. 3A). Secretion of a 120 kDa APP fragment
was induced by co-expression of APP adaptor protein Fe65.
Co-transfection of MT1-MMP or Fe65 alone slightly pro-
moted shedding of the major 56 kDa and 120 kDa APP
fragments into the culture medium, and the shedding
was dramatically enhanced by co-expression of MT1-
MMP and Fe65. Co-transfection of the MT3-MMP gene,
the expression of which is highest in the brain (33), stimu-
lated the shedding of APP fragments more than co-
transfection of the MT1-MMP gene in the presence of
Fe65. Although minor bands of around 90 kDa were
more apparent for the supernatant of MT3-MMP–
transfected cells than that of MT1-MMP–transfected
cells, the APP fragmentation patterns of both seemed to
be identical. Shedding of a 120 kDa APP fragment in the
presence of Fe65, detected with an antibody against the Ab
sequence (6E10), was not affected by the expression of
MT1-MMP or MT3-MMP. These results suggest that
MT1-MMP and MT3-MMP mediate effective cleavage of
APP at multiple sites in the presence of Fe65, and that
the shed APP fragments do not contain the Ab sequence
recognized by the 6E10 antibody. The MT1-MMP active
form was detected in cells expressing MT1-MMP and
APP, as can be seen in Fig. 2A, but was decreased with
co-expression of Fe65.
Other MT-MMP family members were next compared as
to their ability to stimulate the shedding of APP in the
presence of Fe65 (Fig. 3B). Among the six members of
the MT-MMP family examined, MT3-MMP induced the
cleavage and shedding of APP most efficiently, followed
by MT1-MMP and MT5-MMP. The fragmentation patterns
of APP produced by these MT-MMPs were almost identical.
MT2-MMP, MT4-MMP and MT6-MMP did not cause effec-
tive shedding of APP even in the presence of Fe65. MT5-
MMP induced shedding only when co-expressed with Fe65
(data not shown).
To examine the cell-surface localization of APP in cells
expressing MT-MMP, APP was co-expressed with Fe65 in
HEK293T cells stably expressing MT1-MMP or MT3-MMP
in the presence or absence of the MMP inhibitor BB94, and
then the levels of cell-surface APP were compared (Fig. 4A).
APP on the cell-surface was detected as a broad 120 kDa
band for control cells, and treatment of the cells with BB94
increased the cell-surface APP concentration by 2- to 3-
fold. Co-expression of Fe65 with APP was essential for
the cell-surface localization of APP (data not shown).
The level of cell-surface APP in cells expressing MT1-
MMP or MT3-MMP was quite low, and was restored to
the level in control cells by BB94 treatment. Consistent
with the biotin-labeled cell-surface APP levels, cells
expressing MT1-MMP or MT3-MMP shed APP effectively
in the absence of BB94 (Fig. 4B).
Cleavage of the APP Protein by MT3-MMP—To confirm
the direct cleavage of APP by MT3-MMP and to identify the
cleavage sites, a recombinant APP protein consisting of
amino acids 379 to 700 fused to GST was incubated with
recombinant MT3-MMP, and then analyzed by SDS-PAGE
(Fig. 5). The digestion produced five major fragments, the
N-terminal sequences of which showed cleavage of the
A463-M464, N579-M580, H622-S623, and H685-Q686 peptide
bonds of APP, respectively. These results indicate that
MT3-MMP cleaves the APP ectodomain at multiple sites,
including the sequence within the Ab domain (H685-Q686).
Cleavage within the Amyloid b Peptide Domain by MT3-
MMP and Production of CTFs—To identify the CTFs pro-
duced in intact cells via cleavage of APP by MT3-MMP,
APP tagged with the FLAG epitope at the C-terminus
(APP-F) was co-expressed with Fe65 and MT3-MMP,
and then CTFs were analyzed by Western blotting with
antibodies against the FLAG epitope, Ab peptide residues
1–17 (APP amino acid residues 672–688, 6E10), and 17–24
(688–695, 4G8), respectively (Fig. 6). Production of CTFs
by MT3-MMP was stimulated by Fe65 expression. CTFs
detected with the antibody against the FLAG epitope were
also detected with antibody 4G8, but antibody 6E10 failed
to detect the shortest CTF. The results of in vitro digestion
and detection with site-specific antibodies (with epitopes
flanking the cleavage point on both sides) suggest that
Fig. 2. Effects of APP on pro-MMP-2 processing and
MT1-MMP expression. (A) Pro-MMP-2 plasmid (80 ng) was
cotransfected into HEK293T cells cultured in 24-well culture
plates with either the MT1-MMP plasmid (220 ng), APP plasmid
(200 ng), or both. At 48 h post-transfection, cell lysates were ana-
lyzed by gelatin zymography. (B) MT1-FLAG plasmid (200 ng) was
cotransfected with a control or the APP plasmid (300 ng) into
HEK293T cells cultured in 24-well plates. Cells were harvested
48 h after transfection, and then subjected to Western blotting
analysis with anti–FLAG M1 and M2 antibodies as described
under ‘‘EXPERIMENTAL PROCEDURES.’’ Note that the FLAG M1 anti-
body preferentially recognizes the active form MT1-FLAG, which
has a FLAG epitope at the N-terminus, and the M2 antibody recog-
nizes both the latent and active forms of MT1-FLAG.
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MT3-MMP cleaves the H685-Q686 peptide bond within the
Ab sequence.
Effect of MT3-MMP Expression on Ab Peptide Produc-
tion—The Swedish-type mutant of F-APP (F-APP/SW),
which is known to generate the Ab peptide more effectively
than the wild-type APP, was examined for susceptibility to
MT3-MMP (Fig. 7A). Spontaneous shedding of APP/SW
was more vigorous than for the wild-type APP, and was
not significantly affected by Fe65 expression. Expression of
MT3-MMP resulted in effective shedding and fragmenta-
tion of F-APP/SW in the presence and absence of Fe65.
Shedding of F-APP/SW detected with an antibody against
the Ab peptide domain 6E10 was not significantly affected
by the expression of MT3-MMP. Next, the effect of MT3-
MMP expression on Ab peptide production was examined.
The Ab peptide produced by cells transfected with F-APP/
SW accumulated with time, and MT3-MMP expression did
not have a significant effect on Ab peptide accumulation
(Fig. 7B).
Cleavage of APP by MT3-MMP Induces Fe65-Dependent
Transactivation—There have been an increasing number
of reports on the involvement of the APP cytoplasmic
domain in transcription regulation via the formation of a
complex with adaptor protein Fe65 (37, 38). Therefore, we
decided to examine whether MT3-MMP affects APP-Fe65
complex–dependent transcriptional activation. A chimeric
protein in which the Gal4 DNA–binding domain was fused
to the C-terminus of APP (APP-Gal4) was expressed in the
luciferase assay system using COS-1 cells. Significant
transactivation was observed when APP-Gal4 was
co-expressed with Fe65 (Fig. 8). Co-expression of MT3-
MMP with APP-Gal4 and Fe65 caused a significant
increase in the transactivation activity. The addition of
g-secretase inhibitor DAPT significantly suppressed the
transactivation induced by not only Fe65 alone but also
MT3-MMP/Fe65.
DISCUSSION
Using the expression cloning strategy, we previously
identified at least six molecules that exhibit a significant
interaction with MMPs (25–30). In the present study, we
discovered that the expression of APP in HEK293T cells
promoted conversion of the MMP-2 activated intermediate
form to the fully active form in the process mediated by
MT1-MMP. Expression of APP was shown to increase the
Fig. 3. Stimulation of APP shedding by MT-MMP. (A) An
expression plasmid for APP tagged with the FLAG epitope adjacent
to the N-terminus (F-APP) (0.5 mg) or the empty pSG5 plasmid (–)
was cotransfected with 1.0 mg of a control plasmid (–), or an expres-
sion plasmid for MT1-MMP or MT3-MMP (as indicated by the num-
ber above the gel image) with or without the Fe65-HA plasmid
(0.5 mg) into HEK293T cells cultured in 35-mm diameter dishes.
Forty-eight hours after transfection, the culture medium was
replaced with serum-free medium, and the cells were incubated
further for 24 h. Culture supernatants (Sup) or whole cell lysates
(WCL) were examined by Western blotting using the anti–FLAG
M2 antibody, anti-HA antibody, anti–Ab peptide antibody 6E10,
anti–MT1-MMP antibody 113–5B7 or anti–MT3-MMP 117-4E1
antibody. (B) The expression plasmid for F-APP (0.5 mg) and the
Fe65 plasmid (0.5 mg) were co-transfected with 1 mg of the control
plasmid (–) or the expression plasmid for a MT-MMP family
member, as indicated, into HEK293T cells. Culture supernatants
were analyzed for the shedding of F-APP, and whole cell lysates
for the expression of APP and MT-MMP as described above.
MT-MMPs except for MT2-MMP were tagged with the FLAG
epitope and were detected with the anti-FLAG M2 antibody
together with the APP protein. MT2-MMP was detected with
anti–MT2-MMP antibody 162-4E3, which cross reacted with
MT3-MMP (bottom panel).
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Fig. 4. Detection of cell-surface APP. (A) An expression
plasmid for FLAG-APP (0.5 mg) was co-transfected with the Fe65
plasmid (0.5 mg) into HEK293T cells stably transfected with the
empty vector (–), or the MT1-MMP or MT3-MMP plasmid cultured
in 8-well plates. Twenty-four hours after transfection, 1 mM BB94
was added to the indicated cultures, and the cells were incubated
further for 24 h. The cells were then labeled with biotin, and
analyzed as described under ‘‘EXPERIMENTAL PROCEDURES.’’
Cell surface APP labeled with biotin was detected with
IRDye800-conjugated streptavidin (upper panel), while APP
core protein expression was detected with an anti–FLAG M2
antibody labeled with Alexa Fluor 680 (middle panel). Merged
800 and 680 signals reflected the total APP (lower panel).
(B) HEK293T cells that had been mock transfected (–), or stably
expressing MT1-MMP or MT3-MMP were transfected with the
FLAG-APP and Fe65 plasmids, cultured for 48 h as above, and
then incubated further in serum-free medium for 24 h. BB94 was
included in the serum-free medium of the indicated cultures, and
supernatants were analyzed for shed F-APP fragments using
the anti–FLAG M2 antibody. (C) Whole cell lysates of HEK293T
cells stably transfected with the empty pIREShyg vector, pIRES/
MT1 or pIRES/MT3 were subjected to Western blotting with
anti–MT1-MMP antibody 113-5B7 or anti–MT3-MMP 117-4E1 as
indicated.
Fig. 5. Cleavage of recombinant
APP protein by MT3-MMP.
(A) The recombinant APP protein
(5 mg) was incubated with or without
the recombinant MT3-MMP catalytic
domain (0.5 mg) for 3 h, separated by
12% SDS-PAGE, and then stained
with Coomassie Brilliant Blue. The
N-terminal amino acid sequence of
each fragment was determined as
described under ‘‘EXPERIMENTAL
PROCEDURES.’’ Note that the 21 kDa
species co-purified with 70 kDa
species was also cleaved to generate
the smallest fragment. (B) The MT3-
MMP cleavage sites are indicated on
full length APP in relation to the clea-
vage sites for a-, b- and g-secretases.
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concentration of the cell-surface MT1-MMP active form,
which could account for the promotion of pro-MMP-2
activation. Previously we identified type I transmembrane
protein syndecan-1 as an MT1-MMP substrate that also
stimulates MT1-MMP–mediated pro-MMP-2 processing.
Here we also showed that APP acts as a substrate for
MT1-MMP. Since auto-degradation is the most critical
regulatory step of MT1-MMP activity, expression of excess
Fig. 6. Cleavage within the amyloid b pep-
tide domain by MT3-MMP. (A) The recogni-
tion sites for the three antibodies used to detect
APP CTFs are indicated on APP. Anti–APP 6E10
and 4G8 recognize epitopes on opposite sides of
the MT3-MMP cleavage point within the Ab
domain. (B) The APP plasmid (1.6 mmg) tagged
with the FLAG epitope at the C-terminus (APP-
F) was cotransfected with a control plasmid (–),
Fe65 (0.8 mg) or MT3-MMP (2.4 mg), or both into
COS-1 cells cultured in 60 mm diameter dishes.
At 48 h post-transfection, cells were lysed in
400 ml of lysis buffer. A 20-ml aliquot of each
lysate was separated by 4%/10%/16% Tris-
Tricine SDS-PAGE and then immunoblotted
with the 6E10 or FLAG M2 antibody, the
remainder of each lysate being subjected to
immunoprecipitation with anti–FLAG M2
antibody–conjugated agarose beads followed by
detection with 4G8 as described under ‘‘EXPERI-
MENTAL PROCEDURES.’’ Bands with the same
mobility in different lanes are indicated by
arrowheads, arrows and asterisks, respectively.
Note that the band indicated by the asterisk in
the blot of the immunoprecipitated sample over-
lapped with the immunoglobulin light chain
band (panel IP:M2/IB:4G8).
Fig. 7. Effect of MT3-MMP expres-
sion on Ab peptide production.
(A) An expression plasmid for the
Swedish-type mutant form of F-APP
(F-APP/SW) was co-transfected with
a control plasmid or MT3-MMP with
or without the Fe65 plasmid into
COS-1 cells, and then culture super-
natants (Sup) or whole cell lysates
were examined by Western blotting
as described above. (B) The control
plasmid or expression plasmid for
F-APP/SW was co-transfected with
the empty pSG5 or MT3-MMP plasmid
into COS-1 cells, and the culture med-
ium was replaced with serum-free
medium 48 h after transfection. The
culture medium collected after 12 h
or 24 h incubation was examined for
Ab peptide production as described
under ‘‘EXPERIMENTAL PROCEDURES’’
(lanes 2–6). The Ab40 peptide (20 ng)
was used as a standard sample (lane 1).
substrate APP or syndecan-1 may interfere with the auto-
degradation and consequently augment the MT1-MMP
activity against its favourable substrate pro-MMP-2.
Co-expression of Fe65 with APP, which greatly enhances
the cell-surface localization of APP did not enhance but
abrogated the stimulatory effect of APP on pro-MMP-2
activation. Fe65 may affect not only the cell-surface con-
centration but also the structure of APP, and APP is more
susceptible to MT1-MMP in the presence of Fe65, which in
turn cancels the stimulatory effect of APP on MT1-MMP
activity (data not shown).
Higashi and Miyazaki (39) reported that endogenous
MT1-MMP is most likely involved in the cleavage and
shedding of APP in HT1080 cells, and identified a cleavage
site (N579-M580 peptide bond) using an APP fragment and a
recombinant MT1-MMP protein. Here we demonstrated
for the first time that the expression of either
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MT1-MMP, MT3-MMP or MT5-MMP causes cleavage of
APP on the cell surface and shedding of the ectodomain.
We have focused on MT3-MMP as it showed the strongest
effect on APP processing, although it should be noted that
expression of MT5-MMP is neuron-specific (40, 41). Four
cleavage sites were identified within APP as a novel sub-
strate for MT3-MMP using recombinant MT3-MMP and
APP proteins, including the site identified previously
(N579-M580) (39). Another MT3-MMP–cleavage site was
mapped within the Ab peptide sequence (H685-Q686), indi-
cating that MT-MMP could be an a-secretase. Cleavage of
APP within the Ab domain was confirmed by analysis of
CTFs generated by cells expressing MT3-MMP and Fe65.
Since the APP fragmentation seen after cleavage by MT1-
MMP, MT3-MMP and MT5-MMP was almost identical,
MT1-MMP and MT5-MMP may cleave APP at the same
sites as MT3-MMP. Zn2+-dependent metalloproteases
including ADAM (a disintegrin and metalloprotease) 9,
ADAM 10 and ADAM 17 were reported to act as a-secre-
tases for APP (42). ADAMs are also referred to as MDCs
(metalloproteinases, disintegrin, cysteine-rich), and
among these a-secretases, MDC9 also cleaves the APP
H685-Q686 peptide bond (43). As cleavage of APP by an
a-secretase destroys the Ab sequence, it is generally
thought that the a-secretase pathway mitigates amyloid
formation, although this has not been demonstrated
unequivocally. Ab has been shown to be generated in
both the secretory and endocytic pathways in transfected
cell lines and cultured neurons (44–46). It is hypothesized
that Ab is first generated in the trans-Golgi network.
Remaining unprocessed APP is then transported to the
cell surface where it is either cleaved by the nonamyloido-
genic a-secretase or reinternalized into the endosomes. It
was also shown that an a-secretase competes with a b-
secretase for the cleavage of APP in the trans-Golgi net-
work (47). In contrast to secreted Ab, intracellular Ab is
generated in the endoplasmic reticulum/intermediate com-
partment (48–51). Our present study demonstrated that
although expression of MT3-MMP induced the shedding
of cell-surface APP through cleavage of APP within the
Ab domain, it did not significantly affect Ab peptide pro-
duction (Fig. 7). This finding is consistent with the above
observations that Ab is produced in intracellular compart-
ments. Furthermore, the Ab peptide itself was not cleaved
by recombinant MT3-MMP or by cells expressing MT3-
MMP (data not shown).
Co-expression of Fe65 with wild-type APP dramatically
enhanced MT-MMP–mediated cleavage and shedding of
APP, however, it had a negligible effect on the Swedish-
type mutant of APP (Fig. 7A). Fe65 is known to increase
the trafficking of APP to the cell surface (52), where MT-
MMPs function as secretases. The Swedish-type mutant
APP appeared on the cell surface effectively without the
requirement of Fe65 (data not shown).
From the high degree of evolutionary conservation of the
endo- and ectodomains of APP and their widespread tissue
expression, APP has been expected to be involved in a
variety of cellular processes and events. APP and Fe65
are known to be involved in cell motility, which may be
directly related to the proteolytic processing of APP (52).
Since MT1-MMP plays an important role in cell movement
on an extracellular matrix, cleavage of APP by MT1-MMP
may at least in part contribute to the regulation of it. MT1-
MMP expression is highest in the placenta (36). The MT3-
MMP gene, whose expression is highest in the brain and
second highest in the placenta, has been cloned from a
placenta cDNA library (33). In this study we isolated an
APP gene from a human placenta cDNA library by expres-
sion cloning. The results may suggest that cleavage of APP
by MT1-MMP and MT3-MMP plays a role in placenta tis-
sue formation or its function.
g-Secretase cleavage not only leads to the generation of
Ab but also results in the liberation of an intracellular
domain of APP, which has been suggested to potentially
function in nuclear signaling in conjunction with Fe65.
Although a g-secretase is incapable of processing the full
length forms of its substrates, it efficiently cleaves
membrane-anchored truncated C-terminal derivatives
produced on ectodomain shedding (53). MT3-MMP cleaves
APP to generate membrane-anchored CTFs (Fig. 6), which
might be susceptible to further cleavage by a g-secretase.
This may account for the enhancement of APP-Gal4–
mediated transactivation by MT3-MMP. Suppression of
MT3-MMP–induced transactivation by g-secretase inhibi-
tor DAPT may support this hypothesis.
In summary, in addition to the most abundant MT1-
MMP, MT3-MMP and MT5-MMP were shown to cleave
the APP ectodomain at multiple sites including the Ab
sequence, and to induce Fe65-dependent transactivation.
Although the physiological functions of APP remain to be
fully elucidated, MT-MMPs should play an important role
in the regulation of APP functions in tissues including the
central nervous system.
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